Thomas W. Beetham

CIK: 0001741382

Transaction Breakdown

Open Market Buys (P)1 (12.5%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (12.5%)

Derivative conversions

Awards (A)4 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

$Viridian Therapeutics, Inc.\DE logo$

VRDN

Viridian Therapeutics, Inc.\DE

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2026
Tax Payment(F)
Direct
3K shares at avg. $30.19$92K
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2026
Exercise(M)
Direct
9.4K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2026
Tax Payment(F)
Direct
3.1K shares at avg. $29.32$92K
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 2, 2026
Award(A)
Restricted Stock Units
Direct
35.3K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
176.6K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2025
Award(A)
Restricted Stock Units
Direct
37.6K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
225.8K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Sep 27, 2024
Purchase(P)
Direct
5K shares at avg. $23.41$117K

		Type	Shares	Price		Ownership
Mar 3, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Tax Payment(F)	3,048	$30.19	$92,019	Direct
Mar 3, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Exercise(M)	9,409	-	$0	Direct
Mar 3, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Tax Payment(F)	3,138	$29.32	$92,006	Direct
Mar 2, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Restricted Stock Units	35,300	-	-	Direct
Mar 2, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Stock Option (Right to Buy)	176,550	-	-	Direct
Mar 3, 2025	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Restricted Stock Units	37,636	-	-	Direct
Mar 3, 2025	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Stock Option (Right to Buy)	225,814	-	-	Direct
Sep 27, 2024	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Purchase(P)	5,000	$23.41	$117,050	Direct

1-8 of 8 transactions

About Beetham Thomas W.

Beetham Thomas W. (SEC CIK 0001741382) files insider reports with the SEC as Chief Operating Officer of Viridian Therapeutics, Inc.\DE (VRDN).

Signal8 holds 4 ownership filings by Beetham Thomas W., all Form 4s, filed between Sep 30, 2024 and Mar 9, 2026. Those filings report 8 transactions, from Sep 27, 2024 to Mar 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Beetham Thomas W.'s filings is in WALTHAM, MA.

Recent filings by Beetham Thomas W.

Mar 3, 2026: Tax withholding of VRDN shares (Form 4, code F).
Mar 3, 2026: Option exercise of VRDN shares (Form 4, code M).
Mar 3, 2026: Tax withholding of VRDN shares (Form 4, code F).
Mar 2, 2026: Grants or awards of VRDN derivative securities (2 lines, Form 4, code A).
Mar 3, 2025: Grants or awards of VRDN derivative securities (2 lines, Form 4, code A).

Other insiders filing for Viridian Therapeutics, Inc.\DE (VRDN)

Tousignant Jennifer, Chief Legal Officer
Tripuraneni Radhika, Chief Medical Officer
CAIN CHRISTOPHER W., Director
Ajer Jeffrey Robert, Director
Moses Jennifer K., Director
Gheuens Sarah, Director

How to read Form 4 transaction codes